Generex Biotechnology Corp., of Toronto, appointed Mindy Allport-Settle and Peter Amanatides to its regulatory compliance committee...Imagenetix Inc., of San Diego, formed a scientific and medical advisory board to include Jonathan Adachi, Dan Gallaher and Robert Beeten

AGY Therapeutics Inc., of South San Francisco, appointed Larry Powe vice president of clinical development...Biocom, of San Diego, appointed Jack Lief chairman and added new board members Dana Di Ferdinando, Larry Fitch, Mary Lyons, Randall Woods and Kleanthis Xanthopoulos

Nereus Pharmaceuticals Inc., of San Diego, appointed Andrew Dorr chief medical officer and senior vice president of clinical development and regulatory affairs

Neurotech, of Lincoln, R.I., appointed Al Reaves vice president of clinical development

Cardiome Pharma Corp., of Vancouver, British Columbia, appointed Charles Fisher chief medical officer and executive vice president of clinical and regulatory affairs

Aegera Therapeutics Inc., of Montreal, appointed William Peters and Lennie Ryer to its board...Members are Timothy Henry, Robert Simari and Byron Williams...Neurotech, of Lincoln, R.I., appointed Al Reaves vice president of clinical development

AdipoGenix Inc., of Boston, appointed Ed Cannon president and CEO...Alexza Molecular Delivery Corp., of Palo Alto, Calif., appointed Daniel Spyker vice president of clinical and regulatory affairs...Cephalon Inc., of Malvern, Pa., said its chairman, CEO and founder, Frank Baldino, joined the board of Pennsylvania BIO

Saegis Pharmaceuticals Inc., of Half Moon Bay, Calif., appointed Ann Neale vice president of clinical operations...Ventaira Pharmaceuticals Inc., of Columbus, Ohio, promoted Leslie Williams to president and CEO

Cougar Biotechnology Inc., of Los Angeles, appointed Gloria Lee vice president of clinical research and development...Paul Martha to senior vice president and chief medical officer...and Suzanne Bruhn to vice president of global regulatory affairs

Cortex Pharmaceuticals Inc. , of Irvine, Calif., appointed Harry Mansbach chief medical officer and vice president of clinical development...Predix Pharmaceuticals Inc. , of Woburn, Mass., appointed Stephen Donahue vice president of clinical and regulatory affairs...TargeGen Inc. , of San Diego, appointed Charles Theuer vice president of clinical research and chief medical officer

AlgoRx Pharmaceuticals Inc., of Secaucus, N.J., appointed Marc Cantillon vice president of clinical research and Patricia Richards medical director...Myriad Genetics Inc., of Salt Lake City, named Mark Anderson vice president of chemistry, Robert Carlson vice president of discovery biology, Mark Laughlin chief medical officer and vice president of clinical research, and Wayne Laslie chief operating officer and chief commercial officer, all for Myriad Pharmaceuticals Inc

MDS Pharma Services, of Montreal, appointed Beverly Harrison vice president for clinical operations in North America

Conforma Therapeutics Corp., of San Diego, ap-pointed Robert De Jager vice president of clinical research and development and chief medical officer...Genetronics Biomedical Corp., of San Diego, appointed Walter Singleton vice president of clinical and regulatory affairs

Neurological Technologies Inc., of Richmond, Calif., appointed David Levy vice president of clinical development...Novagali Pharma, of Evry, France, appointed Jerome Martinez chairman and Alain Munoz president of the supervisory board...Rosalind Franklin University of Medicine and Science in North Chicago, Ill., elected Ruth Rothstein as chair of its board

Merix Bioscience Inc., of Durham, N.C., appointed Lothar Finke vice president of clinical development, Doug Winship vice president of quality and regulatory affairs, and Michel Greco and Richard Meadows to its board

and Jinsam You, Tony Tegeler and Dariusz Janecki to its scientific team...and Howard Simon senior vice president of human resources and associated general counsel

BioEnterprise Corp., of Cleveland, appointed Glen Gaughan and Michael Lang to its business development team...Chromos Molecular Systems Inc., of Burnaby, British Columbia, appointed Phillip Maples vice president of clinical development and manufacturing, Alan Hardwick vice president of process development and Kathryn Hayashi vice president of finance

Xcyte Therapies Inc., of Seattle, appointed Lawrence Romel vice president of clinical operations and project management

Kalypsys Inc., of San Diego, appointed John McKearn president and chief scientific officer, and added Kenneth Langone and Al Heller to its board...Merrimack Pharmaceuticals Inc., of Cambridge, Mass., appointed Brian Hamilton vice president of clinical and regulatory affairs...OpGen Inc., of Madison, Wis., appointed Thomas Pyle and James Ogle to its board